摘要
结核病化学治疗在2021年度取得了一些进展。一些抗结核新药如吡法齐明、WFQ-228、Q203、DprE1抑制剂、SQ109和LCB01-0371等显示了强大的杀灭结核分枝杆菌作用,部分已进入了临床试验阶段。4个月含利福喷丁和莫西沙星的方案治疗敏感结核病取得了满意的疗效。几种含新药的耐药结核病治疗方案也进行了较为深入的研究。本文就以上进展进行全面阐述。
Certain progress of tuberculosis chemotherapy was made in 2021.Some new anti-tuberculosis agents including pyrifazimine,WFQ-228,Q203,DprE1 inhibitor,SQ109 and LCB01-0371 exhibited powerful effects on killing mycobacterium tuberculosis,and some have entered clinical trial stage.Satisfactory efficacy had been realized for four-month regimen containing rifapentine and moxifloxacin in treating sensitive tuberculosis.Several new drug-resistant TB treatment regimens have also been studied deeply,and comprehensive review onthe above progress is conducted in this paper.
作者
梁晨
唐神结
Liang Chen;Tang Shenjie(Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute,Tuberculosis Clinical Medical Center,Beijing 101149,China)
出处
《国际呼吸杂志》
2022年第13期967-972,共6页
International Journal of Respiration
基金
北京市临床重点专科项目(20201214)。
关键词
结核
化学治疗
抗结核药
治疗新方案
Tuberculosis
Chemotherapy
Antitubercularagents
New treatment regimens
